PAGE 2 - NEW TIMES - |
||
HAWKEYE GIVES LAW ENFORCEMENT AGENCIES POWERFUL, NEW TOOL IN WAR AGAINST DRUNK DRIVERS |
 |
|
The Standardized Field Sobriety Test (SFST), widely used by the law enforcement community to establish "probable cause" is about to get tougher... a lot tougher because of a small, handheld device developed by VisioNetx. Known as the HawkEye, the device permits an officer to detect and record, for evidentiary purposes, minute movements of the eyes. These movements are involuntary and closely mirror the condition of the nervous system at a point in time. Until now, this portion of the test-referred to as gaze nystagagmus-has been conducted manually. As a consequence, it is often challenged in the nation's courts as unreliable. Currently employed as a training too, the HawkEye is expected to go into service sometime in the next eighteen months. More than 500,000 police cruisers could ultimately be equipped with the ruggedly constructed device. According to Richard "Dick" Studdard, a consultant to SC Research Institute and former Officer-in-Charge of the Los Angeles Police Departments (LAPD) Drug Expert Program "The HawkEye overcomes the most serious challenge facing officers administering SFST's-reliability/objectivity-and provides local prosecutors with what is, for all intents and purposes, incontrivertible physical evidence. The implications for law enforcement are enormous."
|
View From
the Top I am happy to announce that the many initiatives we launched in the last six months are producing positive results: Consider the following: The post-merger realignment of personal and corporate resources has been completed; the Boulder office has been shuttered; G&A expenses have been pared; sales and marketing have been refocused (increasing emphasis being placed on sales of IntelliNetx's product lines and development of its sales network); margins have been nudged upward; and VisioNetx has been spun into a majority-owned entity that has been staffed by a team of senior managers and is about to be recapitalized. I, for my part, am working with Dr. Robinson, the inventor of the bone distraction devices that are sold through our OrthoNetx division, to setup distribution channels and develop strategic partnerships to drive the business. And if that isn't enough consider this: Revenues for the first half of 2007 have climbed to more than $1.8 million from $655,000 in FY 2006. Gross profit, as a percentage of sales, has advanced to 21.3%. Total operating expenses have declined by more than $482,096 (See latest 10Q for complete financials or visit www.edgar.gov). All of this holds out enormous promise for the company and you, our shareholders. |
|
REHABILITATING DIZZINESS SUFFERERS
MAKES GOOD BUSINESS SENSE, SO SAYS |
Your Company - A Financial Snapshot* |
|
It is common knowledge that the elderly are prone to falling What is not widely known is the cost, the cost to society and the individual. Not until recently that is. In the Spring of 2007, the management of AcuNetx challenged the MBA students of Pepperdine University's famous Graziadio Business School to examine the problem and determine its extent and cost to the economy. In addition, it asked them to look at possible solutions, i.e. methods and means of reducing the incident. Rising to the occasion, the school elected to assign three groups of executives - all MBA candidates - to the project. Each group was expected to independently study the problem and report back. Now, after fifteen weeks of intensive study and analysis (to include competition and trends) teams, led by Pepperdine Corporate Governor and AcuNetx's Balance Project president, Michael Lesner, have published the results. The findings of the three teams were mirror images of one another, validating the problem and suggesting that a vast, if developing market existed for AcuNetx's products and services, in particular services in which the rehabilitation of patients who suffere from dizziness and falling - but have not sustained an incapacitating injury - figured. The studies concluded that such interventions could dramatically reduce the burden that these patients place on the medical system and society. AcuNetx's management is understandably encouraged by the findings and is carefully weighing the options open to it. Noted Ron Waldorf, president of AcuNetx "Thanks to the good folks at Pepperdine we have a roadmap from which to work." |
Trading Symbol: *see SEC filings for complete disclosure |
|